White Bagging vs Brown Bagging
White bagging and brown bagging both describe the same departure from buy-and-bill: a pharmacy dispenses the drug, and the practice administers something it never owned. They differ in exactly one dimension — who carries the product between the pharmacy and the patient. Under white bagging the pharmacy ships it to the practice; under brown bagging the patient collects it and brings it in. The claim looks the same either way. What the practice can establish about the drug before it is given does not.
Updated 11 min read
On this page
Key takeaways
- The federal government has defined both terms: brown bagging is the patient obtaining the drug at a pharmacy and bringing it to the physician; white bagging is the pharmacy shipping directly to the office or hospital outpatient department.
- Neither is a Medicare requirement. CMS has stated plainly that Medicare does not mandate or encourage either, and that private payers drive them.
- The billing rule is the same for both: the practice cannot bill for a drug it did not purchase, but the administration remains payable.
- To keep the administration from denying, a drug code has to appear on the same or a prior claim carrying a zero billed amount — identifying what was given rather than requesting payment for it.
- The single real difference is custody, and it decides what the practice can verify about storage and handling before administering.
- CMS has recorded its concerns about the patient-carried route specifically: unknown storage conditions, exposure to diversion, and the time, travel and storage burden it puts on the patient.
- A shipped dose is dispensed for one named patient, so it cannot be reassigned when a schedule changes — an inventory problem the practice does not control.
The two terms, as the federal government defines them
These are trade terms, but they are not only trade terms: both appear in federal rulemaking with definitions attached, which is unusual for vocabulary this informal and makes the distinction more precise than most sources treat it. A proposed rule on Part B drug pricing defines them in a single footnote, and it is worth reading as one sentence rather than two.
| Dimension | White bagging | Brown bagging |
|---|---|---|
| Who dispenses the drug | A pharmacy, for one named patient. | A pharmacy, for one named patient. No difference here. |
| Who carries it to the practice | The pharmacy ships it directly to the physician office or hospital outpatient department. | The patient collects it and brings it to the appointment. |
| Who owns it | Not the practice. It never takes title, so it never has the acquisition cost or the inventory. | Not the practice either — and the answer is the same, which is why the billing is the same. |
| What the practice can verify | The product's condition on arrival, and its handling from receipt onward. The leg before that belongs to the shipper. | Only the condition on arrival. Everything between the pharmacy counter and the appointment is outside anyone's records. |
| What can go wrong with the dose itself | It is dispensed for one patient and cannot be reassigned. A cancelled appointment or a changed dose strands it. | The same, plus whatever the journey did to it — temperature, time, handling — which no one recorded. |
| What the claim says | Administration billed; the drug identified on the claim at a zero billed amount. | Identical. The billing rule turns on not having purchased the drug, not on how it travelled. |
Only two rows genuinely differ, and both are about custody. That is the whole distinction, and it is why these are one comparison rather than two separate subjects.
What is identical in both: the claim
CMS's instruction is indifferent to how the drug arrived. If a provider does not purchase a drug but provides the administration service, the physician cannot bill Medicare for the drug — and administering it is an expense to the physician regardless of the source, so the administration is payable if the drug would have been covered had the practice bought it. Both channels sit on the not purchased side of that line, so both get the same answer.
The line that is there to say nothing was owed
One further consequence follows from ownership rather than from channel. Because the practice never bought the drug, the questions that dominate the buy-and-bill model — capital tied up in inventory, a denial that costs product, mandatory assignment closing off any recovery from the patient — do not arise for the drug itself. They are replaced by a different exposure: the practice is responsible for handling and administering something it cannot fully account for, and is paid only for the administration.
What differs: the chain of custody
CMS has put its concerns about the patient-carried route on the record, in the rulemaking for the acquisition program it built in the mid-2000s. Responding to commenters who raised brown bagging as a threat to product integrity, it agreed: the practice may jeopardize product integrity by potentially subjecting the drug to unknown storage conditions and exposing it to diversion, and it may burden the beneficiary by requiring additional time and travel to obtain the product and then requiring appropriate storage of it. Because the authorizing statute indicated that drugs furnished under that program must usually be shipped directly to physicians, CMS said it did not expect brown bagging to occur under it.
Read as an operational statement rather than a policy one, that is a list of the things a practice cannot document about a patient-carried product: where it has been, at what temperature, for how long, and whether it is the product the label says it is. The shipped route removes the unrecorded leg but not the whole problem — the practice can account for the drug from the loading dock forward and no earlier, and a shipment that arrives warm is a question about someone else's handling that the practice discovers.
The form a shipped drug arrives in is its own question
Who decides which arrangement applies
This is the question practices actually have, and the sourced answer is narrower than the internet's. Medicare does not mandate or encourage either arrangement — CMS has said so directly. What the agency records instead is that private payers mandate them, to control drug costs, and that pharmacies increasingly supply drugs to providers that have moved away from purchasing. So the decision is a plan's, exercised through its contract, and it is not something Medicare policy will settle for a practice one way or the other.
Which means the operative document is the contract and the plan's provider manual, not a general rule — and it is a term worth reading before it is invoked rather than after. The related question of which benefit a drug falls under in the first place, and what authorization applies to it, is covered in prior authorization for medications; it is a prior question and often the one that actually decides the arrangement.
A different answer to the waste question, from the one program that ran
What the practice has to have in place
Know the channel before the patient is scheduled
The claim's shape is decided by who bought the drug, and that is settled long before charge entry. A practice that finds out at the chair that this dose came from elsewhere has already scheduled, staffed and prepared on the wrong assumption, and will build the wrong claim.Have a receiving process, and a record it produces
Someone has to receive the shipment, check it against the order and the patient, put it where it belongs and write down that they did. For a patient-carried product the same check happens at the appointment. The record matters because it is the only part of the chain the practice can later stand behind.Write down what happens when the chain cannot be established
A product whose handling cannot be accounted for is a policy question the practice should have answered in advance and in writing — who is told, what is documented, who contacts the dispensing pharmacy and the plan. Deciding it in the moment puts the decision on whoever is standing there.Build the claim with the zero-charge drug line
Administration billed, drug code present on the same or a prior claim at a zero billed amount. It is a small step and it is the difference between a paid administration and a denial that then has to be appealed on a service nobody disputes.Track the doses that arrive for appointments that do not happen
A patient-specific dose cannot be moved to another patient. Cancellations, dose changes and no-shows therefore create a stranded product that belongs to someone else, and somebody has to be responsible for telling the dispensing pharmacy. Left untracked it becomes a dispute about a product the practice never owned.
Common questions
What is the difference between white bagging and brown bagging?
Who carries the drug. Both describe a pharmacy dispensing a drug for a named patient which the practice then administers without ever having purchased it. Under white bagging the pharmacy ships the drug directly to the physician office or hospital outpatient department. Under brown bagging the patient collects it from the pharmacy and brings it to the appointment. Those are the federal definitions, given together in a single footnote to a Part B drug pricing rule. Everything else about the two is the same, including how the claim is built.
How do we bill when the drug was white bagged or brown bagged?
The same way in both cases, because the rule turns on not having purchased the drug rather than on how it arrived. A provider that did not purchase the drug cannot bill for the drug. The administration remains payable — giving the drug is an expense to the practice regardless of where the drug came from — provided the drug would have been covered had the practice bought it. To stop the administration code from denying, a drug code has to be present on the same or a prior claim carrying a zero billed amount. That line identifies what was given; it is not a request for payment.
Does Medicare require white bagging?
No. CMS has stated directly that Medicare does not mandate use of or encourage white bagging or brown bagging, and has described these arrangements as ones private payers mandate to control drug costs. So a requirement to obtain a drug through a particular channel comes from a plan's contract rather than from Medicare policy, and the document that settles it for any given patient is that plan's agreement and provider manual.
Why is brown bagging treated as riskier than white bagging?
Because of an unrecorded leg in the chain of custody. CMS put its concerns on the record when it built its acquisition program: brown bagging may jeopardize product integrity by potentially subjecting the drug to unknown storage conditions and exposing it to diversion, and it burdens the patient with additional time, travel and the need to store the drug appropriately. A shipped product removes that leg — the practice can account for handling from receipt onward — but it does not remove the problem entirely, because the practice still cannot document what happened before the shipment arrived.
What happens to a shipped dose when the patient does not come in?
It is stranded, and it is not the practice's to redirect. The dose was dispensed for one named patient, so it cannot be given to another, and the practice does not own it. Somebody has to be accountable for noticing and for contacting the dispensing pharmacy, and that responsibility is easy to leave unassigned because the product was never on the practice's books. Left untracked it becomes a dispute about property the practice never bought.
Can we still bill for the drug we discarded?
Not when the practice did not buy the drug, because it cannot bill for the drug at all. It is worth knowing that ownership changes this answer generally: under the acquisition program CMS ran, payment reached the vendor only on administration, so discarded drug was not payable to it either — a different result from the one a purchasing practice gets, where the discarded remainder of a single-dose container is payable alongside the dose administered. The attestation rules that apply to a separately payable drug a practice purchased are covered in full elsewhere in this corpus.
Key terms in this article
Defined once, on their own pages.
Continue learning
The model these depart from, and the rest of the drug line.
Medicare billing
The cluster this belongs to — how Medicare's parts, contractors, coverage rules and payment methods fit together.
The Buy-and-Bill Model
The arrangement these two depart from, and the rule that makes buying and billing inseparable.
Medicare Part B drugs and biologicals
Coverage, the average sales price payment framework, and billing units.
Prior authorization for medications
Which benefit pays for a drug, and how drug-level authorization and step therapy are handled.
What a J-Code Is
The code that identifies the drug on the claim, including on the zero-charge line.
Oncology billing
Where these arrangements bite hardest, and the attestation a purchased drug line has to carry about what was discarded.
Authoritative sources
- Medicare Program; International Pricing Index Model for Medicare Part B Drugs, proposed rule, 83 FR 54546 at 54549 (October 30, 2018) (opens in a new tab)
Federal Register via govinfo. Footnote 9 defines both terms in one place: brown bagging is used when the patient obtains the drug at a pharmacy and then brings it to the physician for administration, and white bagging is used when the specialty pharmacy ships directly to the physician office or hospital outpatient department for administration. The body text on the same page records that specialty pharmacies increasingly supply drugs to providers that have moved away from purchasing, that private payers are mandating use of white bagging or brown bagging to control drug costs, and — the sentence this article turns on — that Medicare does not mandate use of or encourage white bagging or brown bagging.
- Medicare Program; Competitive Acquisition of Outpatient Drugs and Biologicals Under Part B, final rule, 70 FR 39022 at 39061 and 39063 (July 6, 2005) (opens in a new tab)
Federal Register via govinfo. At 39063 CMS defines brown bagging as having a beneficiary pick up a drug at a pharmacy and bring it to the physician's office for administration, and agrees with commenters that the practice may jeopardize product integrity by potentially subjecting the drug to unknown storage conditions and exposing the drug to diversion, and may further burden the beneficiary by requiring additional time and travel to obtain the product and then requiring appropriate storage of it; because the authorizing statute indicated that drugs furnished under the program must usually be shipped directly to physicians, the agency said it did not expect brown bagging to occur under it. The same page records that payment reached an approved vendor only upon administration, so discarded drug was not eligible for payment. At 39061 CMS declines to require vendors to perform admixture, noting that such services require specialized staff, training and equipment and are subject to sterile compounding standards with significant effects on shipping, storage and stability, and directs that drugs be shipped in unopened manufacturer's packaging with individual vials unopened and surrounding packaging intact.
- CMS Medicare Claims Processing Manual, Pub. 100-04, Chapter 17 — Drugs and biologicals, § 70.2 (opens in a new tab)
Centers for Medicare & Medicaid Services. Section 70.2, on billing zero charges for drug line items provided at no cost, states that if a provider does not purchase a drug but provides the administration service, the physician cannot bill Medicare for the drug; that the administration of the drug, regardless of the source, is a service representing an expense to the physician and is therefore payable if the drug would have been covered when purchased by the physician; and that under such circumstances, to avoid a drug administration code denial, a drug code must be present on the same or prior claim with a zero billed amount for the drug.